A modified growth-hormone fragment studied in metabolic and obesity research, with limited supportive clinical efficacy data. This record separates established identity and source-linked research context from protocol or commercial fields that are not yet supportable.
FEMETRIC RECORD · PUBLICAOD-9604
Fat LossWeight ManagementBody Composition
Status
Investigational
Related
3
Sources
1
UPDATED 2026-09-13
01
Protocol references
SOURCE-LINKED
LITERATURE-DERIVED REFERENCE
Source-linked research context
No universal administration structure is inferred from the indexed literature. Open the source for the population, intervention and study design.
Route
Oral research · Subcutaneous research
Frequency
See indexed source
Duration
Not indexed
Escalation
Not established
Stage detail pending source extractionStarting and target doses are indexed. Intermediate steps are intentionally not inferred.
LITERATURE-DERIVED REFERENCEJournal of Endocrinology and Metabolism, 2013Verified 2026-09-13
AOD-9604 was designed from the C-terminal region of human growth hormone. Mechanistic and early safety findings do not establish a successful weight-management effect.
Mechanism summaries are stored with field-level source provenance for editorial audit.
07
Related research goals
08
Related peptides
01PEPTIDE
Tesamorelin
A GHRF analogue approved for reduction of excess abdominal fat in adults with HIV and lipodystrophy, with additional research contexts.
Body CompositionFat LossNeuroendocrine
02PEPTIDE
5-Amino-1MQ
A small-molecule NNMT inhibitor studied primarily in preclinical metabolic and adipose-tissue models.
Fat LossBody CompositionMetabolic
03PEPTIDE
Liraglutide
An approved daily GLP-1 receptor agonist studied for type 2 diabetes, weight management and cardiovascular outcomes.